Additional Relevant Details "Results from a Phase 1 study, expected this quarter, will be delayed until Q1 2017. The reasons? The company says one participant in the healthy volunteers trial was murdered and the resultant media attention slowed recruitment. The perpetrator was allegedly a participant in another clinical trial at the same site, the only active site in the healthy volunteers arm. The company adds that Hurricane Matthew also gummed up the works because three trial sites in the CF group were in the path of the storm. The delays mean that the proof-of-concept phase will not begin until later this quarter."

• Seeking Alpha 10/27/2016